Eloxx Pharmaceuticals (ELOX) and The Competition Financial Contrast

Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) is one of 902 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Eloxx Pharmaceuticals to similar companies based on the strength of its institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Earnings & Valuation

This table compares Eloxx Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.

Eloxx Pharmaceuticals’ peers have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and price targets for Eloxx Pharmaceuticals and its peers, as provided by MarketBeat.

Eloxx Pharmaceuticals currently has a consensus price target of $41.50, indicating a potential upside of 154.60%. As a group, “Pharmaceuticals” companies have a potential upside of 30.06%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than its peers.

Institutional and Insider Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 32.8% of shares of all “Pharmaceuticals” companies are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its share price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ peers have a beta of -3.17, indicating that their average share price is 417% less volatile than the S&P 500.

Profitability

This table compares Eloxx Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Summary

Eloxx Pharmaceuticals beats its peers on 7 of the 13 factors compared.

Eloxx Pharmaceuticals Company Profile

(Get Free Report)

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.